AbbVie Inc., a global biopharmaceutical company, has announced the issuance of multiple series of senior notes with varying maturity dates and interest rates. The notes are unsecured, unsubordinated obligations and will rank equally with the company's existing and future unsecured, unsubordinated indebtedness. Interest on each series is payable semi-annually, commencing in 2024. The company intends to use the net proceeds from the sale of the notes to repay loans under the New Term Facility, fund the Cerevel merger consideration, repay outstanding borrowings under the commercial paper program, pay related fees and expenses, and for general corporate purposes. The offering is managed by joint book-running managers Morgan Stanley, J.P. Morgan, BofA Securities, and Citigroup. The notes will not be listed on any securities exchange, and currently, there is no public market for the notes. The date of the prospectus supplement is February 21, 2024.

AbbVie Inc., a global biopharmaceutical company, has announced the issuance of multiple series of senior notes with varying maturity dates and interest rates. The notes are unsecured, unsubordinated obligations and will rank equally with the company's existing and future unsecured, unsubordinated indebtedness. Interest on each series is payable semi-annually, commencing in 2024. The company intends to use the net proceeds from the sale of the notes to repay loans under the New Term Facility, fund the Cerevel merger consideration, repay outstanding borrowings under the commercial paper program, pay related fees and expenses, and for general corporate purposes. The offering is managed by joint book-running managers Morgan Stanley, J.P. Morgan, BofA Securities, and Citigroup. The notes will not be listed on any securities exchange, and currently, there is no public market for the notes. The date of the prospectus supplement is February 21, 2024.